While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Eli Lilly saw its shares jump by 15% on Thursday after unveiling positive results from a clinical trial of its experimental oral drug. ... Getty Images. Should the data remain favorable, ...

Eli Lilly has unveiled plans to invest $27 billion in the construction of four new manufacturing plants in the United States. Getty Images. The new sites will be announced later this year and are ...

Scott Olson / Staff / Getty Images. ... In its Q4 earnings report, Eli LIlly projected that its Zepbound and Mounjaro weight-loss drugs could boost its sales 20% or more in 2024.

Eli Lilly and Co. can restore its image and improve its stock price by doing a better job of touting benefits of the drugs it sells and turning research into new products faster. That’s the ...

Eli Lilly stock is poised to set a new record high Tuesday, after the company reported a surge in sales for its buzzy diabetes drug Mounjaro. Sales of Mounjaro, which has also [gained popularity ...